- Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD)
- The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults
- Validated tools to estimate risk are needed for the more than 35 million adults living with CKD in the U.S.
RIDGEFIELD, Conn. and WILMINGTON, Del., Nov. 4, 2023 /PRNewswire/ — Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict the risk of chronic kidney disease (CKD) progression at all stages of the disease. Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period. These findings were presented in an oral session at the American Society of Nephrology (ASN) Kidney Week conference in Philadelphia, being held from November 1-5, 2023.
“Effective disease-modifying therapies rarely reach the people with chronic kidney disease who are most likely to need them, due to limited recognition of early-stage disease,” said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. “This model may have the potential to help healthcare professionals better identify patients at risk of CKD progression using simple lab results. Physicians need novel tools to evaluate risk of CKD progression, which could assist with earlier diagnosis and treatment.”
The Klinrisk model was developed to predict the risk of CKD progression, defined as either a 40% decline in estimated glomerular filtration rate (eGFR) or kidney failure (dialysis, kidney transplant or eGFR below 10 mL/min/1.73 m2). The model uses machine learning to evaluate risk using age, sex and routinely collected laboratory data, including complete blood cell counts, chemistry and metabolic panels and urinalysis (when available). At least one serum creatinine measurement was required for the validation, and patients were excluded if they did not have at least one year of follow-up time with continuous insurance enrollment after laboratory data was initially collected.
The validation study used data provided by Carelon Research from a diverse population of 4.6 million U.S. adults enrolled in commercial, Medicare and Medicaid insurance plans to assess that the Klinrisk model can predict risk of CKD progression. The model correctly predicted CKD progression in 80-83% of individuals over two years and in 78-83% of individuals over five years, depending on the insurance provider. When urinalysis data was available, the model correctly predicted CKD progression in 81-87% of individuals over two years and in 80-87% of individuals over five years.
“The model is a useful tool to help identify people with high-risk CKD early, before kidney function is lost,” said Navdeep Tangri, M.D., scientific founder of Klinrisk. “We look forward to advancing this model as we aim to bring it to U.S. physicians.”
“As this model requires only demographic information and routine laboratory data, it may have the potential for broad application in a clinical setting to help identify individuals at risk of CKD progression,” said Mark Cziraky, president of Carelon Research. “Earlier identification of CKD risk could help to inform and improve care decisions.”
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at boehringer-ingelheim.com/us/
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
About Carelon Research
Carelon Research, a wholly owned, independently operating subsidiary of Elevance Health, is a healthcare research company committed to improving the future of healthcare with trusted insights powered by evidence. We work with life sciences, government, academia, Elevance Health, and collaborators on a broad range of research solutions focused on generating relevant information needed to help improve health outcomes, lives, and communities.
Sheryl van der Hilst
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: [email protected]
Phone: (914) 772-7973
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.